Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a double-blind, placebo-controlled phase III trial
Annals of Oncology, Volume 17, No. 2, Year 2006
Notification
URL copied to clipboard!
Description
Background: Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous catheters (CVCs). This prospective, double-blind, placebo-controlled, multicenter study evaluated whether prophylactic treatment with a low molecular weight heparin could prevent clinically relevant catheter-related thrombosis. Patients and methods: Patients with cancer undergoing chemotherapy for at least 12 weeks (n = 439) were randomly assigned, in a 2:1 ratio, to receive either dalteparin (5000 IU) or placebo, by subcutaneous injection, once daily for 16 weeks. Patients underwent upper extremity evaluation with either venography or ultrasound at the time of a suspected catheter-related complication (CRC) or upon completion of study medication. The primary end point, as determined by a blinded adjudication committee, was the occurrence of a CRC, defined as the first occurrence of any one of the following: clinically relevant catheter-related thrombosis that was symptomatic or that required anticoagulant or fibrinolytic therapy; catheter-related clinically relevant pulmonary embolism; or catheter obstruction requiring catheter removal. Results: There was no significant difference in the frequency of CRCs between the dalteparin arm (3.7%) and the placebo arm (3.4%; P = 0.88), corresponding to a relative risk of 1.0883 (95% confidence interval 0.37-3.19). No difference in the time to CRC was observed between the two arms (P = 0.83). There was no significant difference between the dalteparin and placebo groups in terms of major bleeding (1 versus 0) or overall safety. Conclusions: Dalteparin prophylaxis did not reduce the frequency of thromboembolic complications after CVC implantation in cancer patients. Dalteparin was demonstrated to be safe over 16 weeks of treatment in these patients. © 2005 European Society for Medical Oncology.
Authors & Co-Authors
Karthaus, Meinolf
Germany, Bielefeld
Evangelisches Klinikum Bethel
Kretzschmar, A.
Germany, Berlin
Helios Klinikum Berlin-buch
Kröning, Hendrik
Germany, Magdeburg
Krankenhaus Altstadt
Biakhov, Mikhail I.
Russian Federation, Moscow
Central Clinical Hospital
Irwin, D.
United States, Berkeley
Alta Bates Comprehensive Cancer Center
Marschner, N.
Germany, Freiburg Im Breisgau
Onkologische Schwerpunktpraxis
Slabber, Coenraad Frederik
South Africa, Pretoria
Little Company of Mary Medical Centre
Fountzilas, George
Greece, Thessaloniki
Aristotle University of Thessaloniki
Garin, A.
Russian Federation, Moscow
Cancer Research Center
Abecasis, N. G.F.
Portugal, Lisbon
Instituto Portugues de Oncologia de Francisco Gentil Lisboa
Baronius, W.
Germany, Chemnitz
Klinikum Chemnitz Ggmbh
Steger, Günther Georg
Austria, Vienna
Universität Wien
Südhoff, Thomas
Germany, Bochum
Universitätsklinikum Knappschaftskrankenhaus Bochum Gmbh
Giorgetti, C.
United States, New York
Pfizer Inc.
Reichardt, Peter
Germany, Berlin
Helios Klinikum Berlin-buch
Statistics
Citations: 224
Authors: 15
Affiliations: 14
Identifiers
Doi:
10.1093/annonc/mdj059
ISSN:
09237534
e-ISSN:
15698041
Research Areas
Cancer
Disability
Study Design
Cohort Study